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Abstract A number of studies suggest that the ubiquitin–
proteasome system (UPS) impairment may underlie neu-
ronal death in Parkinson’s disease. Celastrol is a neuro-
protective agent with anti-inflammatory and antioxidant
properties. The aim of this study was to determine whether
celastrol may exert neuroprotective effects both in vitro
and in vivo under conditions of the lactacystin-induced
UPS inhibition. In the in vitro study, mouse primary cor-
tical neurons and neuroblastoma SH-SY5Y cells were
incubated with lactacystin for 48 h (2.5 and 10 lg/ml,
respectively). The animal study was performed on male
Wistar rats injected unilaterally with lactacystin (5 lg/
2 ll) into the substantia nigra (SN) pars compacta. In the
in vitro study, we did not found any protective effects of
celastrol, given either in the pre- or co-treatment mode.
Moreover, in the higher concentrations, celastrol itself
reduced cell viability, and enhanced the lactacystin-
induced cell death in both types of cells. In the in vivo
study, none of the celastrol doses (0.3–3 mg/kg) attenuated
the lactacystin-induced decrease in the level of dopamine
(DA) and its metabolites or protected nigral dopaminergic
neurons against the lactacystin-induced degeneration. The
highest celastrol dose potentiated the lactacystin-induced
decrease in the level of DA and its metabolites in the
lesioned striatum, and accelerated the lactacystin-induced
increase in the oxidative and total metabolism of DA.
Moreover, when given alone, this dose of celastrol bilat-
erally decreased the number and/or density of dopaminer-
gic neurons in the SN. Our results demonstrate that
celastrol does not induce neuroprotective effects under
conditions of UPS inhibition.
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Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative
disorder characterized by degeneration of dopaminergic
neurons projecting from the substantia nigra pars compacta
(SNc) to the striatum, and the presence of proteinaceous
inclusions called Lewy bodies, which are composed pre-
dominantly of fibrillar a-synuclein and ubiquitinated pro-
teins (Braak et al. 2004; Ehringer and Hornykiewicz 1960).
As a consequence of the loss of striatal dopamine (DA), a
progressive impairment of the control of movements
occurs, inducing akinesia, rigidity, and resting tremor
(Dauer and Przedborski 2003). Although the etiology of
PD remains unknown, it is believed to involve numerous
risk factors, both genetic and environmental.
The ubiquitin-proteasome system (UPS) is the principal
mechanism responsible for the degradation of damaged and
misfolded intracellular proteins, and its failure leads to
protein accumulation and cell death (Ciechanover and
Brundin 2003). A number of studies have suggested that a
failure of the UPS may be an important pathogenic factor in
PD. In fact, it has been found that mutations of the compo-
nents related to the UPS, e.g., parkin and ubiquitin carboxy-
terminal hydrolase L1 (UCH-L1), lead to degeneration of the
nigrostriatal pathway in certain forms of familial PD (Kitada
et al. 1998; Leroy et al. 1998). Moreover, an impaired pro-
teasomal function has been described in the SN of idiopathic
PD (McNaught and Jenner 2001; McNaught et al. 2003).
Besides UPS impairment, cell death in PD has also been
linked to neuroinflammatory processes and excessive oxi-
dative stress (Jenner 2003; Qian et al. 2010). In dopaminergic
neurons, the oxidative deamination of DA by monoamine
oxidase (MAO) and the auto-oxidation of DA results in the
production of hydrogen peroxide which in turn can be con-
verted to hydroxyl radicals to react with and cause damage to
cellular molecules (Hermida-Ameijeiras et al. 2004).
The involvement of oxidative stress in PD is supported
by a postmortem PD brain analysis which involved the
evaluation of several parameters, such as protein and DNA
oxidation, lipid peroxidation, and decreases in reduced
glutathione level (Jenner 1998). The existence of ongoing
inflammatory processes that may contribute to the pro-
gression of PD is supported, e.g., by the presence of acti-
vated microglia, the accumulation of cytokines and nuclear
factor kappa B (NF-jB) pathway activation in the cere-
brospinal fluid and the brain of PD patients (Hirsch and
Hunot 2009; McGeer et al. 1988).
It has been proven that many neuropathological and
behavioral features of PD can be replicated in animal
models of PD, evoked by the use of UPS inhibitors. For
instance, systemic and intracerebral administration of
several UPS inhibitors, including lactacystin, epoxomicin,
and PSI, induces degeneration of dopaminergic neurons
with intracellular inclusions in the SNc as well as behav-
ioral abnormalities in rodents (Fornai et al. 2003; Lorenc-
Koci et al. 2011; Mackey et al. 2013; McNaught et al.
2002a, 2004; Vernon et al. 2011; Xie et al. 2010b). The
toxicity of UPS inhibitors has also been reported in various
cell cultures in vitro (Jantas et al. 2013; McNaught et al.
2002b; Reaney et al. 2006; Rideout et al. 2001). The
inhibition of the UPS has been linked with the occurrence
of neuroinflammatory processes and oxidative stress. For
instance, systemic and intranigral administration of dif-
ferent UPS inhibitors provoke microglial activation in the
SN along with the death of dopaminergic neurons (Ahn and
Jeon 2006). This is consistent with in vitro data showing
microglial activation in cells treated with lactacystin
(Kwon et al. 2008). Furthermore, various parameters of
oxidative stress have been examined in cell lines treated
with UPS inhibitors (Lee et al. 2001). Therefore, it seems
that compounds showing antioxidant and anti-inflamma-
tory activity may protect dopaminergic neurons from the
UPS failure-induced degeneration.
Celastrol, also called tripterine (3-hydroxy-24-nor-2-
oxo-1(10),3,5,7-friedelatetraen-29-oic acid), a quinone
methide triterpene, is a pharmacologically active com-
pound extracted from a Chinese herb Tripterygium Wil-
fordii Hook F (Zhou 1991). Celastrol has strong
antioxidant and anti-inflammatory activity and has been
found to be effective in a number of animal models of
inflammatory (Kiaei et al. 2005; Kim et al. 2009; Li et al.
2008a) and neurodegenerative diseases, e.g., Alzheimer’s
and Huntington’s (HD) diseases (Allison et al. 2001;
Cleren et al. 2005). Studies have shown that celastrol
suppresses microglial activation, pro-inflammatory cyto-
kine production, inducible nitric oxide formation, and lipid
peroxidation (Allison et al. 2001; Sassa et al. 1990). Fur-
thermore, celastrol has been reported to possess a potent
antitumor activity, both in vitro and in vivo, which is
mediated by multiple mechanisms including inhibition of
the UPS and induction of apoptosis (Kannaiyan et al. 2011;
Yang et al. 2006, 2010).
Recently, it has also been demonstrated that celastrol is
able to prevent degeneration of nigrostriatal neurons in the
MPTP-induced neurotoxicity in mice and in a genetic
Drosophila DJ-1A model of PD (Cleren et al. 2005; Faust
et al. 2009). In view of the potential antiparkinsonian-like
effects of this compound, we decided to test its potency in
another PD model, i.e., the lactacystin-induced inhibition
of the UPS, which may operate through different patho-
genic mechanisms from the above-mentioned models.
Therefore, the aim of our study was to determine whether
celastrol may exert a neuroprotective effect both in vitro, in
the lactacystin-induced toxicity in mouse primary cortical
neurons and human neuroblastoma SH-SY5Y cells, and
in vivo, in the rat PD model of lactacystin-induced
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degeneration of nigrostriatal dopaminergic system. Human
neuroblastoma SH-SY5Y cell line is widely used to study
the mechanism of cell death in relation to PD because it
possesses many characteristics of dopaminergic neurons
(Pa˚hlman et al. 1990; Xie et al. 2010a). On the other hand,
mouse primary cortical neurons exhibit typical neuronal
phenotype (Lesuisse and Martin 2002) and we used them to





Dulbecco’s modified Eagle medium (DMEM), fetal bovine
serum (FBS), Neurobasal A medium, and supplement B27
were purchased from Gibco (Invitrogen, Poisley, UK). The
Cytotoxicity Detection Kit came from Roche Diagnostic
(Mannheim, Germany). All the other reagents were from
Sigma-Aldrich (Steinheim, Germany).
Cell Cultures
Mouse Primary Cortical Neurons Brain tissues were
collected from Swiss mouse embryos on day 15/16 of
gestation and were cultured essentially as described pre-
viously (Brewer 1995; Jantas-Skotniczna et al. 2006). All
the procedures were carried out in accordance with the
National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals, and were granted an approval
from the Bioethics Commission as compliant with the
Polish law. The animal care followed the official guide-
lines, and all efforts were made to minimize the number of
animals used and their suffering. Briefly, pregnant females
were anesthetized with a CO2 vapor, killed by cervical
dislocation and subjected to cesarean section in order to
dissect fetal brains. To obtain primary cortical neurons, the
cortex was dissected from embryonic rat brain. The dis-
sected tissues were separately minced into small pieces,
were then digested with trypsin (0.1 %) for 15 min at the
room temperature, triturated in the presence of 10 % fetal
bovine serum and DNAse I (150 Kunitz units/ml), and
finally centrifuged for 5 min at 1,000 rpm. The cells were
suspended in Neurobasal medium supplemented with B27
and plated at a density of 1.5 9 105 cells per cm2 onto
poly-ornithine (0.01 mg/ml)-coated multi-well plates. This
procedure typically yields cultures containing [90 %
neurons and \10 % supporting cells as verified by immu-
nocytochemistry (Fig. 1). The cultures were then
maintained at 37 C in a humidified atmosphere containing
5 % CO2 for 7 days prior to experimentation.
Human Neuroblastoma SH-SY5Y Cells Human neuro-
blastoma SH-SY5Y cells (ATCC, passages 10–20) were
grown in DMEM supplemented with a 10 % heat-inacti-
vated FBS and 0.1 % penicillin/streptomycin mixture. The
cells were maintained at 37 C in a saturated humid
atmosphere containing 95 % air and 5 % CO2. After
reaching 80 % confluency, the cells were subcultured by
trypsinization and seeded into multi-well plates with a
density of 3 9 105 per ml. The cells were differentiated for
7 days with retinoic acid (RA, 10 lM), added to the culture
medium and changed every 3 days. One day before the
experiment, the culture medium was replaced with DMEM
containing antibiotics and 1 % FBS.
Cell Treatment
In the co-treatment mode, primary cortical neurons on day
7 in vitro (7 DIV) were treated with celastrol (0.01, 0.1, 1,
5, and 10 lM) and lactacystin at a concentration of 2.5 lg/
ml (6.6 lM) for 48 h. In our previous study, the chosen
concentration of lactacystin was shown to evoke ca. 40 %
reduction in cell viability (Jantas et al. 2011). When pri-
mary cortical neurons were pretreated with celastrol for 4
and 18 h before exposure to lactacystin (2.5 lg/ml), only
the lower concentrations (0.01, 0.1, and 1 lM) of that
compound were used.
RA-differentiated SH-SY5Y cells were incubated with
lactacystin (2.5–10 lg/ml) for 48 h in order to choose an
effective concentration for study with celastrol. Lactacystin
concentration of 10 lg/ml (26.4 lM), which caused ca.
40–50 % reduction in cell viability after 48 h, was chosen
for the study with celastrol. In the co-treatment mode,
celastrol (0.01, 0.1, 1, and 2.5 lM) was added with lacta-
cystin to RA-SH-SY5Y cells for 48 h. In the pretreatment
mode, RA-SH-SY5Y cells were treated with the lower
concentrations of celastrol (0.01, 0.1, and 1 lM) for 1, 4,
and 18 h before exposure to lactacystin (10 lg/ml).
Celastrol stock solution (10 mM) was prepared in
DMSO, stored at -20 C and its fresh dilutions in distilled
water were prepared for each experimental set. Lactacystin
was dissolved in distilled water. The chemicals were added
to the culture medium at indicated concentrations and
solvent for celastrol was present in cultures at a final
concentration of 0.1 %.
Measurement of Lactate Dehydrogenase (LDH) Release
In order to estimate cell death, the level of LDH, released
from damaged cells into the culture media, was measured
48 h after the treatment of cells. A colorimetric assay was
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applied, according to which the amount of formazan salt,
formed after the conversion of lactate to pyruvate and then
by the reduction of tetrazolium salt, was proportional to
LDH activity in a sample. Cell-free culture supernatants
were collected from each well and incubated with an
appropriate reagent mixture according to the supplier’s
instructions (Cytotoxicity Detection Kit, Roche) at the
room temperature for 20 min. The intensity of red color
formed in the assay and measured at a wavelength of
490 nm, was proportional to the LDH activity and to the
number of damaged cells. Data were normalized to the
activity of LDH released from vehicle-treated cells
(100 %) and were expressed as a percent of the con-
trol ± SEM, established from n = 5 wells per one exper-
iment from 3 separate experiments.
Measurement of Cell Viability (MTT Reduction Assay)
Cell viability assessment was conducted 48 h after the
treatment of cells with the agents. Cell damage was
quantified using a tetrazolium salt colorimetric assay with
3-[4,5-dimethylthylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT). Briefly, MTT was added to each well (at a
final concentration of 0.15 mg/ml) and incubated for
30 min at 37 C; then the dye was solubilized with DMSO
and the absorbance of each sample was measured at
570 nm in a 96-well plate-reader (Multiscan, Labsystem).
Data were normalized to the absorbance in the vehicle-
treated cells (100 %) and expressed as a percent of the
control ± SEM established from n = 5 wells per one
experiment from 2 to 3 separate experiments.
Immunofluorescence
The purity of mouse primary neuronal cell cultures as well
the morphological changes in neurons after 48 h of treat-
ment with lactacystin (2.5 lg/ml) and celastrol (1 lM) was
determined by immunocytochemistry. Cells were seeded in
24-well plates containing culture glass cover slips covered
by poly-ornithine (0.01 mg/ml) at a density of 3 9 105 -
cells/well. After cell treatment at 7 DIV, the cultures were
fixed with 4 % paraformaldehyde, permeabilized with PBS
containing 0.25 % Triton X-100 (PBS-TX-100) and
blocked with 5 % normal goat serum in PBS-TX-100.
Primary antibodies against neuronal (mouse anti-MAP-2,
1:200; Santa Cruz) and glia (rabbit anti-GFAP, 1:400;
Sigma) markers were added and incubated with cells for
120 min at RT. After thrice washing in PBS, the cells were
incubated for 60 min with secondary antibodies: Alexa
Fluor488-labeled goat anti-mouse and Alexa Fluor568-
labeled goat anti-rabbit IgG (Invitrogen, USA) diluted
1:500 in PBS. After washing with PBS, cover slips with
cells were mounted with ProLongGold antifade reagent
(Invitrogen, USA). Cells were examined using a
Fig. 1 Microphotographs from MAP-2 immunofluorescence of 7DIV
mouse primary cortical neurons treated with celastrol (Cel, 1 lM) and
lactacystin (Lac, 2.5 lg/ml) for 48 h (a, d, e, and f). Celastrol
enhanced the reduction in the number of MAP-2 positive cells in
lactacystin-treated primary neuronal cell cultures. The purity of
neuronal cell cultures (about 90 % neurons) was confirmed by
double-immunostainig of vehicle-treated cells with neuronal (anti-
MAP-2) and glia (anti-GFAP) specific markers (a, b, and c)
258 Neurotox Res (2014) 26:255–273
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fluorescence AxioObserver microscope (Carl Zeiss, Ger-
many) equipped with the software Axiovision 3.1 at exci-




The study was carried out on male Wistar rats weighing
between 310 and 445 g at the beginning of the experiment.
The animals were kept under standard laboratory condi-
tions: 5 animals per a large cage, at a room temperature
(22 C) on an artificial light/dark cycle (12/12 h), with free
access to standard laboratory food and water. Experiments
were carried out according to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(publication no. 85–23, revised in 1985) and were approved
by the Institute’s Bioethics Commission. All efforts were
made to minimize the number of animals used and their
suffering.
Drugs
Lactacystin and celastrol were provided by the Sigma-
Aldrich (Steinheim, Germany).
Surgical Procedure
Rats were lightly anesthetized with pentobarbital (Vetbutal,
30 mg/kg i.p. Biowet, Poland) and then were placed in
stereotaxic apparatus. A stainless steel cannula (0.28 mm
o.d.) was inserted unilaterally through a small hole in the
skull and the cannula tip was placed into the left SNc at the
following coordinates: 5.3 mm caudal to the bregma,
2 mm laterally on the left side of the sagital suture, and
7.6 mm beneath the skull surface (Paxinos and Watson
1986). Lactacystin, at a single dose of 5 lg in a volume of
2 ll of sterile redistilled water, was slowly injected into the
SNc at a flow rate of 0.5 ll/min using a Hamilton micro-
syringe connected, via polyethylene tubing, to the cannula.
The cannula was left in place for an additional 5 min to
allow diffusion of the compound away from the cannula
tip. Control rats were treated in the same manner but
received equivalent volume of vehicle instead of lactacy-
stin. The dose of lactacystin was selected on the basis of
our previous research which evaluated the levels of decline
in striatal DA after different doses of intranigrally admin-
istered lactacystin (Lorenc-Koci et al. 2011). We showed
that lactacystin given at a dose of 5 lg/2 ll induced a
distinct (over 80 %) decrease in the striatal DA level
1 week after intranigral administration. After surgery,
animals were returned to their home cages.
Treatment
Eight groups of rats were used for the study. Lactacystin-
and vehicle-injected rats were treated systemically with
celastrol (0.3, 1 or 3 mg/kg/1 ml i.p.) or vehicle (1 ml/kg)
for 4 days (1 day before surgery and then for 3 consec-
utive days). Celastrol was dissolved in a mixture of
dimethylsulfoxide (DMSO) and propylene glycol (1:9,
v/v). A stock solution of celastrol was prepared in DMSO,
stored in small aliquots at -20 C and freshly diluted
before use. The dose of celastrol was chosen on the basis
of other rodent studies (Cleren et al. 2005; Yang et al.
2006).
High Performance Liquid Chromatography (HPLC)
Procedure
One week after surgery, the rats were killed by decapitation
and their left and right striata were rapidly dissected on an
ice-chilled plate and frozen at -80 C until an HPLC
analysis. Tissue samples were weighted and homogenized
in an ice-cold 0.1 M perchloric acid containing 0.05 mM
ascorbic acid. After sonification, the homogenates were
centrifuged at 12,000 rpm for 15 min at 4 C, and the
supernatants were filtered through 0.2-lm cellulose filters
(Alltech Associates Inc.; Deerfield, IL, USA). The super-
natants were used to determine the concentrations of DA
and its metabolites homovanillic acid (HVA), 3,4-dihy-
droxyphenylacetic acid (DOPAC) and 3-methoxytyramine
(3-MT) separately for the right and the left side using the
HPLC system equipped with a C18 column (Thermo Fisher
Scientific Inc., Waltham, MA, USA) and a Coulochem III
detector (ESA Inc.; Chelmsford, MA, USA). The mobile
phase consisted of 50 mM citrate–phosphate buffer (pH
4.2), 0.25 mM EDTA, 0.25 mM sodium octyl sulfonate,
2.4 % methanol, and a 1.3 % acetonitrile. The column
temperature was set at 32 C and the flow rate was main-
tained at 0.8 ml/min. The levels of DA and its metabolites
in test samples were quantified by comparisons of the peak
area with standards that were run on the day of analysis.
Data were collected and analyzed using Chromeleon 6.8
software. Values were expressed as ng/g wet weight of the
tissue.
Immunohistochemistry
Tissue Preparation Posterior parts of the brain containing
the whole SN were fixed in a buffered 4 % paraformal-
dehyde for about 20 h at 4 C and were then immersed (at
4 C) in a buffered 20 % sucrose for cryoprotection. After
a few days, the brains were cut up on a freezing microtome
into 30-lm frontal sections. Every sixth serial section
within the entire length of the SN was sampled. Free-
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floating sections were incubated for 48 h at 4 C in a
mouse monoclonal anti-tyrosine hydroxylase (TH) anti-
body (Chemicon AB), diluted at 1:3,000, and then rinsed in
a phosphate-buffered saline and processed by an avidin–
biotin-peroxidase complex method using an ABC-peroxi-
dase kit (Vector Laboratory) and diaminobenzidine as a
chromogen. The stained sections were mounted onto slides,
dried, dehydrated, cleared in xylene, and cover-slipped in a
Canada balsam.
Stereological Counting TH-immunoreactive (TH-ir)
neurons in the whole SN (pars compacta ? reticulata) of
rats were stereologically counted on both sides of the brain
using a microscope (Leica, DMLB; Leica, Denmark)
equipped with a projecting camera and a microscope stage
connected to a xyz stepper (PRIOR ProScan) controlled by
the computer using the Visiopharm New CAST software
as described previously (Lorenc-Koci et al. 2011). Sys-
temic, uniform, and random sampling were used to choose
sections for the analysis. For stereological estimation, cell
counts were performed within the contours of the SN
[AP = -4.80 to -6.30 mm from the bregma according to
the atlas by Paxinos and Watson (1986)] in at least 8–10
sections at 180 mm intervals. The SN was outlined under a
lower magnification (59), and uniformly sampled dissec-
tor points were randomly used along the whole structure
using the meander sampling. The total number of TH-ir
neurons in the SN was unbiasedly estimated using a three-
dimensional probe under a higher magnification (639)
according to the formula: N = RQ 9 V(ref)/m(dis) 9 RP,
where RQ is the total count of TH-ir neurons in uniformly
sampled dissectors, V(ref)—the total volume of the SN,
v(dis)—the total volume of the dissector (Sterio 1984), and
RP—the total number of all dissector points. A counting
frame of 57.63 9 57.63 lm (3,321.2 lm2), a sampling
grid of 257.33 9 257.33 lm (66,218.7 lm2), and a dis-
sector height of 15 lm below the surface were employed.
Sampling was optimized to produce a coefficient of error
well under the observed biological variability (Gundersen
et al. 1999). The total volume of the SN V(ref) was esti-
mated using Cavalieri’s principle (Gundersen et al. 1999)
according to the formula: V(ref) = t 9 a(p) 9 RP, where t
is the known distance between sections, a(p) is the area
associated with each point of a grid, and RP is the total
number of the counted points over all sections from one
rat.
Data Analysis
All statistical analyses were performed using the Statistica
software package (StatSoft Inc.; Tulsa, USA). Body weight
was expressed for each rat as the percent of the initial value
calculated as the mean value of the individual groups.
Body weight changes were assessed using a two-way
analysis of variance (ANOVA) for repeated measures with
a split-plot design (treatment as a between-subject factor,
and time as a within-subject factor), followed by the
Neuman-Keuls test for a post-hoc comparison. The HPLC-
derived data and immunohistochemical data were analyzed
by a two-way ANOVA, followed by Neuman-Keuls test.
Data from in vitro studies after normalization as a per-
centage of the control ± SEM were analyzed using a one-
way ANOVA and the post-hoc Tukey test for multiple
comparisons. All the hypotheses were tested at a signifi-
cance level of 0.05.
Fig. 2 The effect of celastrol (Cel; 0.01–10 lM) on the lactacystin
(Lac; 2.5 lg/ml)-induced LDH release (a) and the lactacystin-evoked
reduction in cell viability (b) in 7DIV primary cortical neurons. The
cells were co-treated with lactacystin and celastrol for 48 h. The data
were normalized and calculated as a percentage of the control value
and they represent the mean ± SEM from 3 separate experiments
(n = 15). ***p \ 0.001 versus vehicle-treated cells; ##p \ 0.01
versus Lac-treated cells; &&&p \ 0.001 versus Cel (1 lM)-treated
cells




Mouse Primary Cortical Neurons
Lactacystin (2.5 lg/ml) evoked about 50 % increase in
LDH release and 40 % reduction of cell viability after 48-h
treatment of 7 DIV cortical neurons (Fig. 2a, b). Celastrol
(5 and 10 lM) given alone in a concentration-dependent
way induced cell death after 48-h treatment. Concomitant
administration of a subtoxic concentration of celastrol
(1 lM) and lactacystin (2.5 lg/ml) evoked a statistically
significant increase in cell death, measured by the LDH and
MTT assays compared to cells treated with a single agent
(Fig. 2a, b). No additive effect was observed when higher
concentrations of celastrol (5 and 10 lM) were used. The
biochemical data on subtoxic celastrol (1 lM) increasing
the lactacystin-induced cell damage were confirmed by
morphological analysis of anti-MAP-2 immunostained
neurons (Fig. 1).
Pretreatment of neuronal cell cultures for 4 and 18 h
with celastrol (0.01 an 0.1 lM) before lactacystin
(2.5 lg/ml) did not evoke any significant changes in cell
viability measured by the MTT assay when compared to
the lactacystin-treated cells (Table 1). However, like in
the concomitant exposure paradigm, subtoxic celastrol
(1 lM) given 4 and 18 h before lactacystin, significantly
increased the cell damage induced by lactacystin
(Table 1).
Human Neuroblastoma RA-SHSY5Y Cells
Lactacystin (10 lg/ml) evoked a significant increase in
LDH release (ca. 50 %) and ca. 40 % reduction of cell
viability after 48-h treatment (Fig. 3). Celastrol (1 and
2.5 lM) given alone in a concentration-dependent man-
ner induced cell death in RA-SHSY5Y cells (Fig. 4a, b).
A significant increase in cell death was observed after
concomitant treatment of cells with a toxic concentration
of celastrol (1 lM) and lactacystin (10 lg/ml) compared
to cells treated with one agent only (Fig. 4a, b).
Pretreatment of RA-SH-SY cells for 1, 4, and 18 h with
celastrol (0.01 an 0.1 lM) before lactacystin (10 lg/ml
exposure) did not evoke any significant changes in cell
viability/toxicity parameters measured by MTT and LDH
assays (Table 2). However, like in the concomitant expo-
sure paradigm, celastrol (1 lM) given 1, 4, and 18 h before
lactacystin significantly increased cell damage when




General health of the animals was checked daily. Body
weight analysis was performed up to 5 days after the
surgery. A 2-way ANOVA for repeated measures
showed a significant main effect of celastrol
(F3,65 = 7.12, p \ 0.001) and time (F5,325 = 615.05,
p \ 0.001), and significant interactions: celastrol 9 time
(F15,325 = 52.51, p \ 0.001) and lactacystin 9 time
(F5,325 = 15.10, p \ 0.001). A post-hoc analysis
showed the significant decrease in body weight on the
fourth day after surgery in non-lesioned rats treated
Table 1 The effect of celastrol pretreatment on lactacystin-induced
cell damage in primary cortical neurons
Groups Cell viability (% control)
Pre-4 h Pre-18 h
Control 100.00 ± 2.92 99.99 ± 2.82
Cel 1 105.18 ± 2.16 99.74 ± 3.52
Lac 57.11 ± 3.44*** 57.32 ± 1.98***
Lac ? Cel 0.01 65.81 ± 3.52 62.39 ± 1.72
Lac ? Cel 0.1 62.02 ± 2.25 67.48 ± 3.66
Lac ? Cel 1 23.84 ± 0.45###,&&& 39.96 ± 1.86###,&&&
The 7 DIV neuronal cell cultures were pretreated with celastrol (Cel;
0.01; 0.1 and 1 lM) for 4 and 18 h before lactacystin (Lac, 2.5 lg/ml)
administration. After 48 h incubation of cells with lactacystin, the cell
viability was estimated by MTT reduction assay. The data were
normalized and calculated as a percentage of the control value and
they represent the mean ± SEM from 2 separate experiments
(n = 10)
*** p \ 0.001 versus vehicle-treated cells; ### p \ 0.001 versus Lac-
treated cells; &&& p \ 0.001 versus Cel (1 lM)-treated cells
Fig. 3 The time-course of the effect of lactacystin (Lac; 2.5–10 lg/
ml) on the LDH release and cell viability in retinoic acid (RA)-
differentiated SH-SY5Y cells. The cells were treated with lactacystin
for 48 h. The data were normalized and calculated as a percentage of
the control value and they represent the mean ± SEM from 3 separate
experiments (n = 15). ***p \ 0.001 versus vehicle-treated cells
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with the highest dose of celastrol (3 mg/kg) (Fig. 5). In
the lesioned animals, the significant decrease in body
weight was observed on the third day after surgery in
groups treated with 1 and 3 mg/kg of celastrol. How-
ever, only the highest celastrol dose (3 mg/kg) induced
an irreversible body weight loss in both lesioned and
non-lesioned animals, even after celastrol withdrawal
and some of these rats (27 %) died before the end of
the experiment. No mortality was reported in other
groups of animals. Groups treated with lower doses of
celastrol (0.3 or 1 mg/kg) ceased to lose weight on the
second day after celastrol withdrawal. On the seventh
Fig. 4 The effect of celastrol (Cel; 0.01–2.5 lM) on the lactacystin
(Lac; 10 lg/ml)-induced LDH release (a) and the lactacystin-evoked
reduction in cell viability (b) in RA-SH-SY5Y cells. The cells were
co-treated with lactacystin and celastrol for 48 h. The data were
normalized and calculated as a percentage of the control value and
they represent the mean ± SEM from 3 separate experiments
(n = 15). *p \ 0.05 and ***p \ 0.001 versus vehicle-treated cells;
##p \ 0.01 and ###p \ 0.001 versus Lac-treated cells; &p \ 0.05 and
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day after surgery, body weight in these two groups was
similar and was approximately 90 % of the initial value
(data not shown).
Striatal DA Metabolism
One week after lesion, the rat striata were examined for
DA, DOPAC, 3-MT, and HVA content by HPLC. A two-
way ANOVA was used to analyze the main effect of
lactacystin and the highest dose of celastrol (3 mg/kg),
separately for the ipsilateral (lesioned) and contralateral
(intact) side of the striatum (Fig. 6a–d). In the ipsilateral
striatum, the main significant effects of lactacystin were
observed for DA, DOPAC, 3-MT, and HVA levels
(F1,33 = 446.51, p \ 0.001; F1,33 = 301.42, p \ 0.001;
F1,33 = 175.20, p \ 0.001; F1,33 = 169.65, p \ 0.001,
respectively), whereas the main effect of celastrol was
apparent for 3-MT and HVA levels (F1,33 = 16.86,
p \ 0.001; F1,33 = 4.51.86, p \ 0.05, respectively). There
were also significant interactions between lactacystin and
celastrol for DA, DOPAC, and HVA levels (F1,33 = 4.29,
p \ 0.05; F1,33 = 23.64, p \ 0.001; F1,33 = 15.55,
p \ 0.001, respectively). A Newman–Keuls post-hoc test
showed no decrease in the level of DA in the ipsilateral
striatum of rats treated with celastrol alone compared to the
ipsilateral striatum of the control animals (Fig. 6a); on the
other hand, there was an increase in DOPAC and HVA
levels (Fig. 6b, d), and a decrease in 3-MT level (Fig. 6c).
In contrast, lactacystin induced a dramatic decrease in the
Fig. 5 The effect of lactacystin (Lac) and celastrol (Cel) on the rat
body weight. Lactacystin (5 lg/2 ll) was administered unilaterally
into the left SNc. Celastrol (0.3, 1 or 3 mg/kg i.p) was given
subchronically for 4 days (1 day before surgery and then for three
consecutive days). The number of animals per group: 8–10. The data
were calculated as a percentage of the control value and they are
expressed as the mean ± SEM. The symbols indicate significant
differences in the post-hoc test: *p \ 0.05, **p \ 0.01, ***p \ 0.001
versus control
Fig. 6 The effect of unilateral
administration of lactacystin
(Lac; 5 lg/2 ll) into the left
SNc and intraperitoneal
administration of celastrol (Cel;
3 mg/kg) on the level of DA
(a) and its metabolites DOPAC
(b) 3-MT (c) and HVA (d) in
the striatum. The rats were
killed 7 days after lactacystin
administration. Lactacystin
induced a strong decrease in the
striatal levels of DA and its
metabolites, which was
potentiated by celastrol. The
number of animals per group:
8–10. The values are expressed
as the mean ± SEM. The
symbols indicate significant
differences in the post-hoc test:
*p \ 0.05, **p \ 0.01,
***p \ 0.001 versus control
group; &p \ 0.05, &&p \ 0.01
versus Lac group, on the same
side of the striatum
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levels of striatal DA and its metabolites DOPAC, 3-MT,
and HVA compared to the control group (Fig. 6a–d).
Combined treatment with lactacystin and celastrol induced
a further decrease in the striatal DA, DOPAC, and 3-MT
levels, and showed a tendency to decrease HVA level
compared to the lactacystin group (Fig. 6a–d).
As regards DA catabolism (Fig. 7a–c) in the ipsilateral
striatum, the main effects of lactacystin were observed for
MAO-dependent oxidative DA deamination (DOPAC/
DA), COMT-dependent O-methylation (3-MT/DA), and
total DA catabolism (HVA/DA) (F1,33 = 73.75, p \ 0.001;
F1,33 = 20.91, p \ 0.001; F1,33 = 31.23, p \ 0.001,
respectively), and the main effects of celastrol for the
DOPAC/DA and HVA/DA ratios (F1,33 = 7.82, p \ 0.01;
F1,33 = 10.16, p \ 0.01, respectively); however, there was
no significant interaction between lactacystin and celastrol
(p [ 0.05). The Newman-Keuls post-hoc test revealed that
celastrol alone did not change, whereas lactacystin signif-
icantly increased, the striatal metabolic ratios of DOPAC/
DA, 3-MT/DA and HVA/DA in the ipsilateral striatum
compared to the control group (Fig. 7a–c). Combined
treatment with lactacystin and celastrol induced a further
increase in the metabolic ratios of DOPAC/DA and HVA/
DA compared to the lactacystin group (Fig. 7a, c).
In the contralateral striatum, the only significant main
effect of celastrol (3 mg/kg) was observed for DOPAC, 3-MT,
and HVA as well for the DOPAC/DA, 3-MT/DA, and HVA/
DA ratios (F1,33 = 7.98, p \ 0.01; F1,33 = 4.51, p \ 0.05;
F1,33 = 14.19, p \ 0.001; F1,33 = 4.93, p \ 0.05;
F1,33 = 4.63, p \ 0.05; F1,33 = 11.33, p \ 0.01, respec-
tively). A post-hoc analysis showed that celastrol significantly
increased DOPAC and HVA levels (Fig. 7b, d) as well as the
HVA/DA ratio (Fig. 7c) compared to the contralateral stria-
tum of the control group and lactacystin group (rats which
received lactacystin on the opposite side of the SN).
The effects of the lower doses of celastrol (0.3 and
1 mg/kg) were presented in Table 3. In the ipsilateral
striatum, a two-way ANOVA revealed the main significant
effects of lactacystin for DA, DOPAC, 3-MT, and HVA
levels (F1,49 = 433.85, p \ 0.001; F1,49 = 319.28,
p \ 0.001; F1,49 = 307.67, p \ 0.001; F1,49 = 408.89,
p \ 0.001, respectively), whereas the main effect of cel-
astrol was apparent for DA, DOPAC, and HVA levels
(F2,49 = 3.71, p \ 0.05; F2,49 = 8.49, p \ 0.001;
F2,49 = 4.55, p \ 0.05, respectively). Generally, there was
no difference in the effects of two lower doses of celastrol
on DA metabolism. In contrast to the highest dose of cel-
astrol, there was no significant interaction between
Fig. 7 The effect of unilateral
administration of lactacystin
(Lac; 5 lg/2 ll) into the left
SNc and intraperitoneal
administration of celastrol (Cel;
3 mg/kg) on DA turnover in the
striatum. MAO-dependent
oxidative DA deamination (a),
COMT-dependent O-
methylation (b), and total DA
catabolism (c), are expressed as
a percent of DOPAC/DA,
3-MT/DA, and HVA/DA,
respectively. Lactacystin




potentiated the lactacystin effect
on the DOPAC/DA and HVA/
DA ratios. The number of
animals per group: 8–10. The
values are expressed as the
mean ± SEM. The values are
expressed as the mean ± SEM.
Symbols indicate significant
differences in the post-hoc test:
* p \ 0.05, ***p \ 0.001
versus control group;
& p \ 0.05, &&p \ 0.01 versus
Lac group, on the same side of
the striatum
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lactacystin and any of two lower doses of celastrol
(p [ 0.05). Unlike the sharp decreases in the levels of
striatal DA and its three metabolites after lactacystin
treatment, as revealed by the Newman-Keuls post-hoc test,
only a moderate, but significant decrease in DOPAC level
was observed after celastrol (0.3 and 1 mg/kg).
As regards DA catabolism in the ipsilateral striatum, the
main effects of lactacystin were observed for all three
catabolic ratios: DOPAC/DA, 3-MT/DA, and HVA/DA
(F1,49 = 145.73, p \ 0.001; F1,49 = 132.90, p \ 0.001;
F1,49 = 36.26, p \ 0.001, respectively), and the main
effects of celastrol were seen only for the 3-MT/DA ratio
(F2,49 = 11.85, p \ 0.001). There was also a significant
interaction between lactacystin and celastrol for the 3-MT/
DA ratio (F2,49 = 9.68, p \ 0.001). In the post-hoc ana-
lysis, similarly to the highest celastrol dose, there was no
effect of the lower doses of celastrol on any of the catabolic
ratios. In contrast, there was no further increase in the
DOPAC/DA or HVA/DA ratios after combined treatment,
but there was a significant increase in the 3-MT/DA ratio.
In the contralateral striatum, the only significant main
effect of celastrol was observed for the DOPAC level, as
well for the DOPAC/DA ratio (F2,49 = 4.81, p \ 0.05;
F2,49 = 17.64, p \ 0.001, respectively). A post-hoc ana-
lysis showed that two doses of celastrol slightly but sig-
nificantly decreased the DOPAC/DA ratio, as compared to
the control and lactacystin group.
Stereological Analysis of the SN
Representative photomicrographs of nigral TH-ir neurons
from individual treatment groups are shown in Fig. 8. On
the lesioned side of the SN, the main effect of lactacystin
on the number of TH-ir cells (F1,38 = 128.84, p \ 0.001)
as well as the main effect of lactacystin and celastrol on the
density of TH-ir cells (F1,38 = 133.64, p \ 0.001;
F2,38 = 5.08, p \ 0.05, respectively) were described. As
regards the number and the density of TH-ir cells in the
intact SN (Fig. 9a, b), only a significant overall effect of
celastrol (F2,38 = 7.66, p \ 0.01; F1,38 = 9.77, p \ 0.001,
respectively) was revealed. A post-hoc analysis showed
that lactacystin significantly reduced both the number and
the density of TH-ir cells in the lesioned SN (Figs. 8e, 5a,
b). None of the doses of celastrol (1 and 3 mg/kg) pre-
vented the loss of TH-ir cells or its density in the lesioned
SN, when given jointly with lactacystin (Fig. 9a, b). Fur-
thermore, when given alone, the higher celastrol dose
reduced the number and/or density of TH-ir cells by ca.
30 % on both sides of the SN (Fig. 8c, d). Interestingly, the
decrease in the number and density of TH-ir cells induced
by celastrol (3 mg/kg) on the intact side of the SN was
higher in the lactacystin group (group treated with lacta-
cystin on the opposite side) than in the group treated with
celastrol alone (Fig. 9a, b). As regards the volume of the
SN, the main effect of lactacystin (F1,38 = 10.10,
p \ 0.01) was observed on the lesioned side, whereas the
main effect of celastrol was revealed on the intact side
(F2,38 = 4.75, p \ 0.05); however, a post-hoc analysis did
not reveal any significant differences in comparison to the
control groups (Fig. 9c).
Discussion
The main finding of the present study is that celastrol does
not exert a neuroprotective effect under conditions of UPS
inhibition. Furthermore, at higher doses, this compound
accelerates toxicity triggered by lactacystin and induces
cell death, when given alone in both in vitro and in vivo
studies.
Toxicity of lactacystin has been confirmed in many
studies using in vitro models (Jantas et al. 2013; McNaught
et al. 2002b; Reaney et al. 2006; Rideout et al. 2001). It is
generally accepted that the UPS inhibition is the main
mechanism responsible for that effect (Fenteany et al.
1995). It was proven that lactacystin at a concentration of
10 lM, hence lower than those used in our experiments,
induced a pronounced inhibition (75–90 %) of the chy-
motrypsin, trypsin-like, and post-glutamyl peptidase
activity in PC12 cells (Fornai et al. 2003). Previous studies
revealed that suppression of the UPS function by lactacy-
stin led to the accumulation and aggregation of misfolded
proteins, and resulted finally in induction of neuronal
apoptosis via the release of cytochrome c from mitochon-
dria and the activation of caspase-3-like proteases (Li et al.
2008b; Qiu et al. 2000).
In the present study, we demonstrated, using two dif-
ferent cell cultures (mouse primary cortical neurons and
human neuroblastoma RA-SH-SY5Y cells) and a wide
range of celastrol concentrations (from 0.01 to 10 lM) that
celastrol, given concomitantly with lactacystin, did not
protect cells from its toxic effect. Furthermore, we did not
find any beneficial effect of celastrol, when that compound
was given at various time points (from 1 to 18 h) before
lactacystin exposure. The possible explanation for the toxic
effect of celastrol in the present study is that this com-
pound, besides its anti-inflammatory and antioxidant
properties, is also a potent proteasome inhibitor with
preferential inhibition of proteasomal chymotrypsin-like
activity (Yang et al. 2006). At a concentration of 2.5 lM,
celastrol inhibited chymotrypsin-like activity by ca.
40–60 % in purified rabbit 20S proteasome, human cul-
tured prostate tumor cells and Xenopus laevis A6 kidney
epithelial cells (Walcott and Heikkila 2010; Yang et al.
2006). At the same concentration, it induced accumulation
of ubiquitinated proteins in cells and changes in cell
266 Neurotox Res (2014) 26:255–273
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phenotype, accompanied with cytoskeletal disorganization
and apoptosis (Walcott and Heikkila 2010; Yang et al.
2006). Hence, it may be speculated that inhibition of the
UPS by celastrol may be one of the mechanisms respon-
sible for its toxic effects, especially under conditions of
UPS impairment by lactacystin.
Although we found no neuroprotective potency of cel-
astrol, neither given as pretreatment, nor administered
jointly with lactacystin, it should be mentioned that effect
of celastrol may be biphasic, being protective at low doses
and toxic at higher ones. For instance, in PC12 cells, its
best protective effect against polyglutamine toxicity or the
tert-butyl hydroperoxide (t-BHP)-induced oxidative stress
was obtained at 0.1 lM (Sun et al. 2010; Zhang and Sarge
2007), and a toxic effect at 1.6 lM (Sun et al. 2010). In
HeLa cells expressing a mutant polyglutamine protein, a
significant decrease in cell death was achieved only at
concentrations between 0.4 and 1.6 lM (Zhang and Sarge
2007). The neuroprotective effect of low concentrations of
celastrol (0.001 and 0.01 lM) was also found in our recent
Fig. 8 Representative
photomicrographs of coronal
sections of the rat SN showing
the distribution of TH-ir
neurons ipsilateral (a, c, e,
g) and contralateral (b, d, f,
h) to the injection site. a,
b Control rats; c, d rats after
4-day celastrol (3 mg/kg)
treatment; e, f rats after
unilateral lactacystin (5 lg/
2 ll) injection into the SNc; g,
h rats after lactacystin (5 lg/
2 ll) administration into the
SNc and 4-day celastrol (3 mg/
kg) treatment. Calibrations
bars = 200 lm. (SNc substantia
nigra pars compacta, SNr
substantia nigra pars reticulata)
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study, but only in cells incubated for longer time in a low-
serum medium (Jantas et al. 2013). Therefore, it seems that
celastrol has a narrow therapeutic window, and its pro-
tective or cytotoxic effect not only depends mainly on its
concentration, but also on other factors, e.g., the cell type
and culture conditions. However, in the present study, we
did not find any protective effects of celastrol against
lactacystin-induced toxicity, even when we used the former
compound at the low, non-toxic concentrations (0.01 and
0.1 lM). Thus, it appears that under conditions of the
strong UPS inhibition by lactacystin, celastrol is not able to
protect cells.
Similarly to the above-mentioned neuroprotective
effects of celastrol, there are some data demonstrating
neuroprotective effect of lactacystin against toxicity
induced by low doses of 6-OHDA (Inden et al. 2005;
Yamamoto et al. 2007) or by glutamate (Maher 2008; van
Leyen et al. 2005). On the other hand, treatment with other
UPS inhibitors enhanced 6-OHDA-induced toxicity in
different cell cultures (Elkon et al. 2001; Ho¨glinger et al.
2003). These contradictory results may be explained by the
fact that 6-OHDA at low doses increases protein degra-
dation and the UPS activity, presumably in response to
oxidative stress (Elkon et al. 2001, 2004). In contrast,
higher doses cause their marked decline (Elkon et al.
2004). Therefore, it may be speculated that neuroprotection
induced by UPS inhibitors is facilitated in those models in
which the primary detrimental factor used to destroy neu-
rons is not directly related to UPS inhibition.
On the basis of the above-mentioned studies, it appears
that the final effect of the UPS inhibition (cell survival or
death) depends strongly on the concentration of the
inhibitor used and the duration of its effects (and conse-
quently on the level of UPS inhibition over time). This
assumption is consistent with the results of a microarray
study (Yew et al. 2005) performed on mouse primary
cortical neurons treated with lactacystin that showed dif-
ferent effects at varying post-treatment time points: an up-
regulation of genes involved in the neuroprotective
response to UPS inhibition at an early time point (e.g.,
heat-shock protein (HSP) 70, HSP22, genes of the UPS,
and cell cycle inhibitors), followed by a proapoptotic
response (genes involved in apoptosis, oxidative stress, and
inflammatory responses). It has been shown that HSP70
plays a protective role by, for instance, preventing protein
misfolding and aggregation (Yenari 2002), and its up-reg-
ulation appears to be specific for the cell death mediated by
UPS inhibitors (Yew et al. 2005). In fact, celastrol has been
found to enhance various HSP levels in vitro; however, the
concentrations that enhance HSPs are only slightly lower
than the concentrations that are toxic for dopaminergic
cells (Chow and Brown 2007). Moreover, in t-BHP-
induced cytotoxicity celastrol increases HSP70 expression
Fig. 9 The effects of unilateral administration of lactacystin (Lac;
5 lg/2 ll) into the left SNc and intraperitoneal administration of
celastrol (Cel; 1 and 3 mg/kg) on the stereologically estimated
number (a) and density (b) of TH-ir neurons, counted in coronal
sections of the rat brain, and the volume of the SN (c). Celastrol was
administered subchronically for 4 days (1 day before surgery, and
then for 3 consecutive days). The rats were killed 7 days after
lactacystin administration. Celastrol did not attenuate the dramatic
decrease in the number and density of TH-ir neurons on the lesioned
side of the SN, induced by lactacystin. The number of animals per
group: 5–9. Each bar represents the mean ± SEM. The symbols
indicate significant differences in the post-hoc test: *p \ 0.05,
**p \ 0.01, ***p \ 0.001 versus control group; #p \ 0.05 versus
Lac group, on the same side of the striatum
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at concentrations higher than those that are protective in
this model (Sun et al. 2010). Therefore, it may be sug-
gested that the increase in HSP70 expression is not a truly
neuroprotective property of celastrol, but is rather a result
of the defensive reaction of cells against its toxic effect.
The above assumption is supported by the fact that the
increase in HSP70 content was also observed in surviving
dopaminergic neurons of rats treated with a low dose of
lactacystin (Pastukhov et al. 2013).
The question arises why primary cortical neurons were
more vulnerable to lactacystin toxicity compared to RA-SH-
SY5Y cells (2.5 vs. 10 lg/ml, respectively) in the present
study. These results are not consistent with the previously
described greater sensitivity of various cell lines of tumoral
origin to the UPS inhibition compared to normal cells
(Adams et al. 1999; Almond and Cohen 2002). These dis-
crepancies may be the result of RA-induced differentiation
of SH-SY5Y cells which makes them more resistant to
lactacystin toxicity. In fact, a very recent study on SH-SY5Y
cells showed a protective effect of RA against the toxic effect
of another UPS inhibitor epoxomicin (Cheng et al. 2013). In
line with this assumption, we recently found that lactacystin
at a dose as low as 0.25 lg/ml decreased cell viability in
undifferentiated, but not RA-differentiated, SH-SY5Y cells
(Jantas et al. 2013). Likewise, the toxic concentration of
celastrol in undifferentiated SH-SY5Y cells was ten times
lower than in RA-SH-SY5Y ones (Jantas et al. 2013). Other
evidence for the increased resistance of RA-SH-SY5Y cells
comes from the present study, namely after treatment of both
types of cells with lactacystin and celastrol the increase in
cell death was obtained in primary cortical neurons after
subtoxic concentration of celastrol, whereas in RA-SH-
SY5Y cells a toxic concentration of this compound was
required to evoked the same effect.
The lack of the protective effect of celastrol against the
lactacystin-induced toxicity in vitro was supported in the
present study by utilizing the rat PD model in which
degeneration of dopaminergic neurons was caused by
unilateral administration of lactacystin directly into the
SNc (Lorenc-Koci et al. 2011; Niu et al. 2009; Mackey
et al. 2013; McNaught et al. 2002a). The advantage of the
lactacystin model over other conventional animal models
of PD is related to the fact that it replicates cardinal
pathological features of PD, i.e., the nigral degeneration
and aberrant protein degradation. We showed that lacta-
cystin (5 lg/2 ll) induced a strong decrease (83 %) in DA
level in the lesioned striatum 1 week after surgery, com-
pared to the intact side. Parallel to the change in DA
content, a significant decline in the levels of the DA
metabolites DOPAC (intraneuronal metabolite), 3-MT
(extraneuronal metabolite), and HVA (total metabolite) in
the lesioned striatum was observed. Moreover, lactacystin-
evoked acceleration of MAO-dependent N-oxidation
(DOPAC/DA), COMT-dependent O-methylation of DA
(3-MT/DA), and the total DA catabolism (HVA/DA) which
means that both extraneuronal and intraneuronal DA
catabolism were increased after lactacystin administration.
The enhanced DA catabolism, especially oxidative catab-
olism catalyzed by MAO, may at least partly contribute to
neuronal death by inducing oxidative stress (Jenner 2003).
In fact, there is evidence showing a close mutual rela-
tionship between inhibition of the UPS function and oxi-
dative stress (Davies 2001; Lee et al. 2001).
In contrast to the lactacystin group, animals treated with
any of celastrol doses showed no decrease in the striatal
DA level. There were, however, some differences in the
levels of DA metabolites between groups treated with two
lower (0.3 and 1 mg/kg) and the highest (3 mg/kg) dose of
celastrol. In the former two groups, only a small but sig-
nificant decrease in the level of DOPAC in the ipsilateral
striatum was revealed, whereas in the latter group, DOPAC
and HVA levels were elevated, but 3-MT level was
decreased in both sides of the striatum. Thus, celastrol
seems to influence in the opposite way the intraneuronal
DA catabolism, diminishing or increasing it, depending on
the dose. This assumption is consistent with the direction of
changes in DA catabolic ratios of DOPAC/DA which were
decreased after lower doses (the effect more clearly visible
on the contralateral side), but tended to rise after the
highest dose. Such an increase in the oxidative pathway of
DA catabolism may sensitize dopaminergic neurons and
make them more vulnerable to lactacystin toxicity. In fact,
only the treatment with the highest dose of celastrol
accelerated the lactacystin-induced decrease in the striatal
level of DA (from 83 to 97 %) and its metabolites com-
pared to the intact side of the striatum. Furthermore, the
highest dose of celastrol enhanced the lactacystin-induced
acceleration of the MAO-dependent oxidative catabolism
and the total catabolism of DA, but it was not accompanied
by a simultaneous increase of extraneuronal DA catabolism
(3-MT/DA). This implies that exacerbation of DA decline
may result from the shifting of DA metabolism from
O-methylation towards the N-oxidation pathway. On the
other hand, in groups treated with lactacystin and the lower
celastrol doses, 3-MT/DA ratio substantially increased on
the ipsilateral side compared to the lactacystin group. Such
enhanced catabolism of DA through COMT-dependent
O-methylation is supposed to constitute an antioxidant
defense mechanism against oxidative stress (Miller et al.
1996). However, since this increase was not accompanied
by a substantial increase in DA level, the effect of celastrol
seems to be insufficient to overcome the toxicity of
lactacystin.
Our biochemical findings were confirmed in the present
study by the immunohistochemical data. We demonstrated
that lactacystin induced a strong reduction in the number
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and the density of TH-ir neurons in the lesioned SN one
week after surgery. None of the two celastrol doses (1 and
3 mg/kg) prevented the lactacystin-induced loss of nigral
TH-ir neurons. Furthermore, the higher celastrol dose was
toxic by itself, having reduced the number and density of
cells by ca. 30 % on both sides of the SN. It is worth noting
that the decrease in the number/density of TH-ir neurons on
the intact side of the SN in rats treated with a 3 mg/kg of
celastrol was greater in the lactacystin group (i.e., the
group treated with lactacystin on the opposite side) com-
pared to the rats administered with celastrol alone. The
above finding suggests that lactacystin may to some extent
spread to the contralateral side of the SN. This assumption
is consistent with a most recent study showing a bilateral
loss of TH-ir neurons in the SNc and ventral tegmental
area, especially after high doses (10 and 20 lg) of unilat-
erally administrated lactacystin (Mackey et al. 2013).
Although the dose of lactacystin we used (5 lg) was too
low to damage neurons on the contralateral side of the SN,
it could sensitize neurons to celastrol toxicity.
The other finding of our in vivo study was that celastrol,
besides induction of degeneration of dopaminergic neu-
rons, may exert systemic toxicity by producing weight loss
and mortality in rats. These findings are consistent with
studies of Zhu et al. (1996) who revealed toxic effects of
celastrol on digestive, urogenital and blood circulatory
system in dogs. In our study, only the highest dose of
3 mg/kg of celastrol produced adverse effects and 27 % of
rats from this group died before the end of the experiment.
Interestingly, a similar dose, given once or twice daily, was
found to be effective against MPTP- and 3-nitropropionic
acid-induced toxicity in mice and rats, respectively, as well
as against the tumor in mice, without inducing toxic side-
effects (Cleren et al. 2005; Yang et al. 2006). Moreover,
the i.p. LD50 of celastrol for Wistar rats was determined to
be much higher (20.5 mg/kg) (Li et al. 2013). On the other
hand, one study demonstrated a high mortality (40 %) in
mice during celastrol (4 mg/kg) treatment (Raja et al.
2011). Therefore, further studies are required to determi-
nate the safety and tolerability of that compound.
Although in the present study, no beneficial effects of
celastrol against lactacystin toxicity were found, it should
be noted that some researchers showed neuroprotective
effects of that compound in other animal models of PD. For
instance, Cleren et al. (2005) demonstrated that celastrol
significantly diminished the MPTP-induced loss of dopa-
minergic neurons in the mouse SN and attenuated striatal
DA and DOPAC depletion, probably by attenuation of the
MPTP-induced increases in TNF-a and NFjB immunore-
activity, or induction of HSP70. In another study, utilizing
a genetic Drosophila DJ-IA model, celastrol increased
brain DA level and the number of TH-ir neurons in the
dorsomedial cluster (Faust et al. 2009). The main reasons
for such contrasting results obtained in the present and the
above-mentioned studies are most probably the differences
in the models of PD which reflect diverse aspects of the
pathophysiology of PD and may involve different cellular
mechanisms of neurodegeneration. In particular, lactacy-
stin, which is an irreversible UPS inhibitor, induces long-
term inhibition of the UPS, since ca. 40–50 % decrease in
chymotrypsin-like activity can be observed in mouse ven-
tral midbrain (VM) 3–4 weeks after lactacystin adminis-
tration (Li et al. 2010; Zhu et al. 2007). On the other hand,
the Drosophila DJ-IA model that refers to an early-onset
form of familial PD does not seem to be directly related to
UPS dysfunctions (Bonifati et al. 2003; Faust et al. 2009).
It has been demonstrated that DJ-1 mutations result in
mitochondrial defects and increased neuronal vulnerability
to oxidative stress (Takahashi-Niki et al. 2004; Wang et al.
2012). However, DJ-1-deficient mice do not show any UPS
dysfunctions, in either the striatum or VM (Yang et al.
2007). The question arises whether MPTP is able to
decrease UPS activity in vivo. It has recently been found
that only continuous administration of MPTP with an
osmotic minipump produces a long-lasting (2 weeks)
inhibition of the UPS and formation of inclusion bodies
stained for ubiquitin and a-synuclein in the mouse SN. In
contrast, conventional MPTP injection induces only a brief
UPS inhibition (\24 h) and fails to produce protein
aggregation (Fornai et al. 2005). Interestingly, under con-
ditions of conventional MPTP administration, the revers-
ible UPS inhibitor PSI either does not enhance
neurodegeneration (Kadoguchi et al. 2008), or even pro-
tects dopaminergic neurons against the MPTP-induced
toxicity in mice (Oshikawa et al. 2009), thus confirming the
earlier observation from in vitro models that the severity
and duration of the UPS inhibition may determinate the
final, beneficial or adverse effect of the UPS inhibitors.
In conclusion, the presented in vitro and in vivo studies
demonstrate, for the first time to our knowledge, that celas-
trol, a compound which has been shown to be neuroprotec-
tive in some models of PD, is no longer protective under
conditions of UPS inhibition. Since UPS failure seems to
contribute to the pathogenesis of PD, the compounds with a
profile similar to celastrol, which, besides anti-inflammatory
and antioxidant properties, are also potent proteasome
inhibitors, may accelerate the progression of the disease.
Therefore, any putative possible pathogenic factors,
including those related to the UPS inhibition, must be taken
into account in a search for potentially neuroprotective drugs
useful in PD treatment strategies.
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